US Stock Movement: Twist Bioscience surged on October 9 as price target was raised and trading was launched
Bitget异动解读2026/10/09 14:05Twist Bioscience October 9 Surge Interpretation
Keywords: Target Price Increase, Trading Launch
1. On October 9, Barclays maintained a "Buy" rating on Twist Bioscience and raised its target price from $112 to $215. The rating and target price adjustment constituted a direct company-level catalyst for the day.
2. On October 8, Trade.xyz announced the launch of TWST trading and support for up to 10x leverage. Twist Bioscience mainly focuses on gene synthesis and related biotechnology tools, and the expansion of trading channels has improved the stock’s accessibility.
3. On August 3, the company disclosed that for the fiscal quarter ending June 30, revenue increased by 23% year-on-year to $118.4 million. DNA synthesis and protein solutions revenue grew by 39%, NGS application revenue grew by 12%, and gene shipments increased by 56% year-on-year to approximately 369,000. The main business continues to grow rapidly.
(Disclaimer: This content is generated by AI summarizing publicly available information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US stock movement: Arcutis surged on October 9 due to ZORYVE data and infant eczema news
Elon Musk says it is possible for SpaceX to be valued at over 10 trillions dollars.
Elon Musk stated: "It now appears that a valuation of over $10 trillion for SpaceX (SPCX.US) is a possible outcome. Previously, I thought this could never happen. Although the probability of this outcome remains extremely low, the speed at which this probability is rising is accelerating rapidly, and the magnitude of the acceleration is also increasing."
Crypto prices
More
